<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357562</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/28</org_study_id>
    <nct_id>NCT03357562</nct_id>
  </id_info>
  <brief_title>MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis</brief_title>
  <acronym>CFMR-lung</acronym>
  <official_title>MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the diagnostic sensitivity of MRI to detect changes in&#xD;
      Helbich-Bhalla scoring over time in patients with cystic fibrosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) is caused by the cystic fibrosis transmembrane conductance regulator&#xD;
      (CFTR) gene mutation and represents one of the most frequent and lethal inherited disease in&#xD;
      Caucasian. However, thanks to better treatments that slow down the progression of pulmonary&#xD;
      disease, the median life expectancy has reached 41 years and there are nowadays more CF&#xD;
      patients older than 18-year-old than younger. Chronic lung disease is the main manifestation&#xD;
      and represents more than 90% of CF morbidity and mortality. However, there is a need for&#xD;
      biomarkers more sensitive than clinical and functional findings for a personalized management&#xD;
      of patients. Computed tomography (CT), owing to its high spatial resolution and contrast, is&#xD;
      the standard of reference in imaging for depicting lung structural alterations. But CT is an&#xD;
      ionizing technique, rising concern in cancer risk associated to cumulated radiation dose. To&#xD;
      date, Magnetic Resonance Imaging (MRI) is a radiation-free technique which has been&#xD;
      demonstrated to add meaningful functional information that cannot be reached using CT. Recent&#xD;
      advances in 3-dimensional ultra-short echo time (3D-UTE) imaging have been shown promising to&#xD;
      improve lung MR imaging quality. A clear delineation between airway wall and lumen was&#xD;
      obtained, thanks to submillimeter voxel size, enabling readers to estimate both bronchial&#xD;
      thickening and dilatation with very good concordance with CT, independently from the&#xD;
      magnitude of score. The combination of pulse sequence may rather benefit from the potential&#xD;
      of MRI to get more complete insight into inflammatory processes by combining several&#xD;
      contrasts, as compared to other ionizing methods. Novel MR methods have been shown promising&#xD;
      in assessing lung changes with high resolution and therefore could be proposed instead of CT&#xD;
      for radiation- free repeated, life-long follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of MRI to detect lung changes</measure>
    <time_frame>Month 36</time_frame>
    <description>deterioration or improvement measured by the Helbich-Bhalla scoring with CT as gold standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of MRI to Helbich-Bhalla scoring change</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Sensitivity of MRI to Helbich-Bhalla scoring change in various subgroups of patients according to age, centers and MR scan manufacturers, and new treatment drug use (Ivacaftor/lumicaftor: Orkambi Ø or Ivacaftor : Kalydeco Ø ) from CT and MR examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT / MR concordance</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Concordance between CT and MR in amplitude of Helbich-Bhalla scoring variations at M0 and M36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the 3D-UTE MR sequence</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Sensitivity of the 3D-UTE MR sequence alone to detect change in Helbich-Bhalla scoring as compared to CT performed at M0 and M36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging quality of the 3D-UTE MR</measure>
    <time_frame>Month 0, Month 12, Month 24 and Month 36</time_frame>
    <description>using a likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between a specific Helbich-Bhalla MR score and the amplitude of change</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Correlation between a specific Helbich-Bhalla MR score with clinical and functional data, and concordance with the amplitude of change between M0 and M36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of a lung MR protocol</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Accuracy of a lung MR protocol including T1-weighted and T2-weighted sequences to diagnose allergic broncho-pulmonary aspergillosis (ABPA) in CF patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility in detecting lung structural abnormality</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>MR and CT reproducibility in detecting lung structural abnormality at the segmental level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility in overall Helbich-Bhalla scoring</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>MR and CT reproducibility in overall Helbich-Bhalla scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between Helbich-Bhalla scoring and clinical questionnaire</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Correlations between Helbich-Bhalla scoring measured with MRI and CT and clinical questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between Helbich-Bhalla scoring and exacerbation rate</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Correlations between Helbich-Bhalla scoring measured with MRI and CT and exacerbation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between Helbich-Bhalla scoring and clinical pulmonary functional test</measure>
    <time_frame>Month 0 and Month 36</time_frame>
    <description>Correlations between Helbich-Bhalla scoring measured with MRI and CT and clinical pulmonary functional test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>lung MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lung MRI without contrast injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lung MRI</intervention_name>
    <description>lung MRI without contrast injection</description>
    <arm_group_label>lung MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female children (age ≥ 8 y.o) and adult patient with a diagnosis of cystic&#xD;
             fibrosis provided by genetic and swear test older than 8 years. Subgroups of patients&#xD;
             will be defined according to:&#xD;
&#xD;
               -  age: younger or older 18y.o. We expect around 50% in different subgroups. In case&#xD;
                  of, we reach 50% in one of these groups, patient recruitment will continue for&#xD;
                  both groups until the expected number of patients in the study is reached.&#xD;
&#xD;
               -  brand name of magnet: Siemens, General Electric or Philips&#xD;
&#xD;
          -  new drugs use: association Ivacaftor/lumicaftor (OrkambiØ) or Ivacaftor only (Kalydeco&#xD;
             Ø) ) We expect approximately 20% to 50% of patients treated&#xD;
&#xD;
          -  Informed consent provided to the patient or/and to legal representative for adults and&#xD;
             to parents for the children&#xD;
&#xD;
          -  Patient concerned by articles L 1121-6, L 1121-7, and L 1121-8 (persons deprived of&#xD;
             their liberty by a judicial or administrative decision, minors, persons of legal age&#xD;
             who are the object of a legal protection measure or unable to express their consent)&#xD;
             if the expected benefit for such persons justifies the foreseeable risk incurred&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients without any social security or health insurance&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  Patients with previous pulmonary transplantation or planned for transplantation in the&#xD;
             year following inclusion&#xD;
&#xD;
          -  MRI contraindications:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francois Laurent, MD, PhD</last_name>
    <phone>+33 557656368</phone>
    <email>francois.laurent@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gael Dournes, MD, PhD</last_name>
    <phone>+33 557656542</phone>
    <email>gael.dournes@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaël Dournes, MD, PhD</last_name>
      <phone>+33 557656542</phone>
      <email>gael.dournes@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rkia Achkir</last_name>
      <phone>+33 557623252</phone>
      <email>rkia.achkir@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Macey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fayon, MD, PhD</last_name>
      <phone>+33 556799824</phone>
      <email>michael.fayon@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Francois Chateil, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Bassient, Md</last_name>
      <phone>+33 157022092</phone>
      <email>laurence.bassinet@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Alain Rahmouni, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Ferretti, MD, PhD</last_name>
      <phone>33 476765241</phone>
      <email>gferretti@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Boubou Camara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Remy-Jardin, MD</last_name>
      <phone>+33 32044 67 06</phone>
      <email>martine.remy@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Reynaud-Gaubert, MD, PhD</last_name>
      <phone>+33 491966145</phone>
      <email>MartineLouise.REYNAUD@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Christophe Dubus, MD, PhD</last_name>
      <phone>04.91.96.60.49</phone>
      <email>JeanChristophe.DUBUS@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Petit, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Lenval</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Boyer, MD</last_name>
      <phone>33 492030312</phone>
      <email>corinne.boyer@lenval.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand-Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harriet Corvol, MD, PhD</last_name>
      <phone>+33144736910</phone>
      <email>harriet.corvol@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hubert Ducou-Lepointe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfant Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Sermet, MD, PhD</last_name>
      <phone>+33 144494887</phone>
      <email>isabelle.sermet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Grenet, MD</last_name>
      <phone>+33 146252582</phone>
      <email>d.grenet@hopital-foch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau-Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baptiste Morel, MD</last_name>
      <phone>+33 247473614</phone>
      <email>baptiste.morel@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>CT</keyword>
  <keyword>MRI</keyword>
  <keyword>radiation dose</keyword>
  <keyword>contrast agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

